KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Payables (2016 - 2025)

Nektar Therapeutics has reported Payables over the past 16 years, most recently at $10.8 million for Q4 2025.

  • Quarterly results put Payables at $10.8 million for Q4 2025, down 6.83% from a year ago — trailing twelve months through Dec 2025 was $10.8 million (down 6.83% YoY), and the annual figure for FY2025 was $10.8 million, down 6.83%.
  • Payables for Q4 2025 was $10.8 million at Nektar Therapeutics, down from $15.6 million in the prior quarter.
  • Over the last five years, Payables for NKTR hit a ceiling of $23.7 million in Q3 2021 and a floor of $2.6 million in Q2 2023.
  • Median Payables over the past 5 years was $11.2 million (2024), compared with a mean of $11.6 million.
  • Biggest five-year swings in Payables: tumbled 78.79% in 2023 and later surged 160.86% in 2024.
  • Nektar Therapeutics' Payables stood at $9.7 million in 2021, then soared by 33.17% to $13.0 million in 2022, then fell by 24.13% to $9.8 million in 2023, then rose by 17.38% to $11.6 million in 2024, then dropped by 6.83% to $10.8 million in 2025.
  • The last three reported values for Payables were $10.8 million (Q4 2025), $15.6 million (Q3 2025), and $14.3 million (Q2 2025) per Business Quant data.